VBI 1501A

Drug Profile

VBI 1501A

Alternative Names: VB 1501; VBI-1501A

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VBI Vaccines
  • Class Cytomegalovirus vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cytomegalovirus infections

Most Recent Events

  • 27 Jul 2017 Interim immunogenicity data from a phase I trial in Cytomegalovirus infections (in healthy volunteers) released by VBI Vaccines
  • 02 May 2017 Adverse events data from a phase I trial in Cytomegalovirus infections released by VBI Vaccines
  • 20 Sep 2016 VBI Vaccines completes enrolment in a phase I trial in Cytomegalovirus infections (Prevention, In volunteers) in Canada , NCT02826798)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top